ABSTRACT
Acute scrotal conditions form a significant proportion of cases in surgical ward. They contribute to significant morbidity in younger age group and mortality in older age group. In this study we have attempted to study the causes, aetiology, prevalence and management of acute scrotal conditions. The prevalence in descending order was Acute epididymo orchitis, Pyocele, Hematocele, Fournier’s gangrene, Acute filarial scrotum, Testicular torsion, Scrotal abscess, Mumps orchitis, scrotal trauma. Of these Epididymo orchitis, mumps orchitis and Filarial scrotum were treated conservatively with antibiotics, rest and scrotal support. Fournier’s gangrene, Scrotal abscess and scrotal trauma with wound debridement and reconstruction. Pyocele and hematocele by incision and evacuation of pus and blood respectively. Testicular torsion is treated by surgical de rotation and B/L orchidopexy. Orchidectomy was done if warranted in hematocele, pyocele, and testicular torsion.
ABSTRACT
Based on the results of 20 cases with mumps orchitis who were treated with Prednisolon (25-30 mgs per day in 5 days) or Triamcinolon (5-6 mgs per day in 5 days), the author showed that corticoids could either release fever and pain within 24 hours or 48 hours, or reduce the swelling of orches faster in comparison with the other group of patients. Nevertheless, corticoids could not prevent the orches shrinking
Subject(s)
Orchitis , Mumps , Therapeutics , Adrenal Cortex HormonesABSTRACT
Mumps orchitis represents the most common complication of mumps infections and occurs in 5 to 37% of the populations. The most important danger is the risk of testicular atrophy up to 50% of affected testis which results in sterility. Two patients with mumps orchitis received systemic treatment with Interferon-alpha2(INF-alpha2)(3x06IU per day) for 7 days. All acute symptoms and signs of mumps orchitis disappeared within 4-7 days of INF-alpha2 therapy. No incidence of testicular atrophy was observed at the 19 and 6 months follow-up, respectively. No significant adverse effects of drug were occurred during treatment. We recommend the immediate interferon therapy, as soon as mumps orchitis manifests, to relieve clinical manifestation and to prevent testicualr atrophy and resulting infertility.
Subject(s)
Humans , Male , Atrophy , Follow-Up Studies , Incidence , Infertility , Interferons , Mumps , Orchitis , TestisABSTRACT
Mumps orchitis occurs in 20 to 35% of cases of mumps in adolescent boys and young men. Spermatogenesis is irreversibly damaged in about 30% of testes involved in mumps orchitis and marked atrophy of the affected testis is the rule but there is no specific treatment. Therefore, we have investigated in a prospective study whether systemic interferon-alpha2B treatment may be considered a causal therapy for patients with mumps orchitis Ten patients with mumps orchitis ( unilateral 8, bilateral 2 ) received systemic treatment with interferon-alpha 2b ( 3xl0' IU per day ) for 7 days. Hormonal levels(LH, FSH, Testosterone, Prolactin, Estradiol) of pre and post-treatment with interferon were normal range. All acute symptoms of mumps orchitis disappeared within 2 to 3 days of treatment with interferon.Within 7 days the volume of the affected, enlarged testis returned to normal. In 3 of 4 patients pretreatment examination revealed asthenospermia, while 3 months after interferon treatment, as well as during the entire followup period normospermia was found. During 3 to 18 months of followup no incidence of testicular atrophy was observed. No severe adverse effects occurred during treatment. We conclude that systemic treatment with lnterferon-alpha2b appears to be highly effective in symptomatic treatment, as well as preventing sterility and testicular atrophy after mumps orchitis. Further investigation on larger populations should be performed to substantiate these results.